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The purpose of the present study was to prepare a novel domperidone hydrogel. The domperidone dispersion was prepared
by the solvent evaporation method. The characteristics of domperidone dispersion were measured by dynamic light scattering
(DLS), scanning electronic microscopy (SEM), diﬀerential scanning calorimetry (DSC), X-ray diﬀractometry, and solubility test,
respectively. Domperidone hydrogel was prepared by directly incorporating the domperidone dispersion in Carbopol hydrogel to
increase its mucoadhesive properties to gastrointestinal tract (GIT). The in vivo pharmacokinetic and pharmacodynamic studies
were investigated to evaluate the relative oral bioavailability and the propulsion eﬃcacy of domperidone hydrogel as compared
with market domperidone tablet (Motilium tablet). The particle size of domperidone dispersion in distilled water was 454.0nm.
The results of DSC and X-ray indicated that domperidone in dispersion was in amorphous state. The solubility of domperidone
in the dispersion in distilled water, pH of 1, 5, and 7 buﬀer solution was 45.7-, 63.9-, 13.1-, and 3.7-fold higher than that of
raw domperidone, respectively. The area under the plasma concentration curve (AUC0−24) in domperidone hydrogel was 2.2-fold
higherthan that of tablet. The prolonged propulsion eﬃcacy inthe domperidone hydrogel group compared to thatintablet group
was observed in the pharmacodynamic test.
1.Introduction
Domperidone, a dopamine D2 receptor antagonist, is used
as a prokinetic and antiemetic agent for the treatment
of gastroparesis, nausea, and vomiting [1]. Domperidone
is a weak base with good solubility in acidic pH but in
alkaline pH, its solubility is signiﬁcantly reduced [2]. The
oral bioavailability of domperidone has been reported at
the range of 13–17% [3]. The poor aqueous solubility
may be one possible reason for its low bioavailability. In
order to increase the bioavailability of domperidone, a
controlled release dosage form has been prepared to increase
the solubility of domperidone in the alkaline medium [2].
Recently, the domperidone gastric ﬂoating matrix tablet
has been demonstrated to prolong the presence of the
dosage form in the stomach or the upper small intestine
and increase the amount of dissolved domperidone in
gastric medium [4]. Therefore, it may play a key role of
enhancing the solubility of domperidone in the aqueous
medium.
The oral bioavailability of amorphous drugs can be
improved because of the increase of apparent solubility
[5–7]. In addition, supersaturation of the drug in the
gastrointestinal tract, particularly in theupperintestine, may
lead to faster permeation rates through biomembranes and
thus, enhance absorption [8–10]. Many polymers have been
used as crystallization inhibitors to form amorphous solid
dispersion in order to avoid forming lower energy crystalline
states. These polymeric crystallization inhibitors orient pref-
erentially to the water/drug particle interface to stabilize the
particles. Recently, itraconazole amorphous nanoparticles
and amorphouscompositionshavebeenreported toincrease
the supersaturation of itraconazole [11–19]. In addition,
felodipine amorphous nanoparticles were investigated by2 Journal of Drug Delivery
an evaporation method using PVP as a hydrophilic poly-
meric carrier [20]. The author indicated that the interaction
atthemolecularlevelofdrugwith thepolymercarrier would
control the physical state and the particle size of drug-carrier
system. Being controlled by the relatively strong interaction
of felodipine with PVP, the drug forms amorphous particles
in the nanometer size range. Otherwise, for felodipine/PEG
system, the drug is dispersed as crystals having sizes in the
microrange.
Mucoadhesive hydrogel prepared by bioadhesive poly-
mer has the property of increasing the time of retention
in GIT when it orally administrated. Carbopol is one of
the currently most widely used mucoadhesive hydrogel
polymers. Now, a relevant amount of work has been
done on its bioadhesive properties [21–24]. In particular,
Carbopols may be used in oral preparations to improve
GIT retention time. It has been reported that the combi-
nation of nanosized drug particles with Carbopol hydro-
gel would increase mucoadhesive properties of the drug
particles, and then achieve a suﬃciently high bioavail-
ability [25]. When nanosized drug particles are directly
dispersed in the hydrogel, the mucoadhesive polymer will
be absorbed onto the particle surface and the contact time
of drug particles with GIT mucous membranes will further
increase.
The aim of the present study was to prepare a novel
domperidone hydrogel and evaluate its in vivo properties.
The domperidone dispersion was prepared by a solvent
evaporation method using polyvinylpyrrolidone K30 as a
hydrophilic polymer. The dynamic light scattering (DLS)
technique was used to measure the particle size of the
domperidone dispersion in distilled water. Morphological
and thermal behaviors of the domperidone dispersion were
examined by scanning electronic microscopy (SEM) and
diﬀerential scanning calorimetry (DSC), respectively. Also,
X-rays were used to investigate the characteristic of drug
crystallinity. The solubility of domperidone in dispersion
was tested. Domperidone hydrogel was prepared by directly
incorporating the domperidone dispersion in Carbopol
hydrogel. The in vivo pharmacokinetic and pharmacody-
namic studies were investigated to evaluate the relative
oral bioavailability and propulsion eﬃcacy of domperidone
hydrogel compared with market domperidone tablet (Motil-
ium tablet).
2.Materialsand Methods
2.1. Materials. Domperidone (the purity more than 99.5%)
was purchased from the Baotai Pharmaceutical Co. of
Shanxi, China. Polyvinylpyrrolidone K30 (PVP K30)w a s
obtained from ISP Technologies, INC. (A local agent in
Beijing, China). Carbopol 974 P was kindly provided by
BF Goodrich Specialty Chemicals (a local agent in Bei-
jing, China). The market domperidone tablet, Motilium
tablet (10mg/per tablet, Lot: 0611211114, Xian Janssen Co.
China) was purchased from Beijing pharmacy. Absolute
alcohol was obtained from the Beijing Chemical Factory.
All other chemicals were of analytical grade or HPLC
grade.
2.2. Animals. Healthy adult male beagle dogs weighting 9–
11kg and male Kunming mice weighing 18–21g were sup-
plied by the Department of Experimental Animals (Peking
University Health Science Center) and maintained under
natural light/dark conditions. Animals were acclimatized for
7 days prior to experiment and were allowed free access to
standard food and water. Temperature and relative humidity
were maintained at 25◦C and 50%, respectively. All care and
handling of animals were performed with the approval of
InstitutionalAuthorityforLaboratoryAnimalCareofPeking
University.
2.3.Preparation ofDomperidone Dispersion and PhysicalMix-
ture. Domperidone dispersion was prepared by dissolving
accurately weighed amounts of domperidone (50mg) and
PVP K30 (500mg) (1:10w/w) in dehydrated ethanol in
a closedglass receiver.After completedissolution, thesolvent
was evaporated under reduced pressure at 50◦Ct of o r ma
uniform ﬁlm. Desiccation was completed in a vacuum oven
until constant weight was achieved. After adding distilled
water, the mixture was sonicated for ﬁve minutes and
then lyophilized to form a pulverous domperidone disper-
sion using an FD-2B Lyophilizer (Boyikang Co., Beijing,
China).
Physical mixture was prepared by simple intensive mix-
ing of domperidone and PVP K30 previously grinded for
1-2min in a mortar until a homogeneous mixture was
obtained. The resulting mixture was sieved through grade 60
and then stored in a desiccator at room temperature until
use.
2.4. Particle Size Analysis. T h ep a r t i c l es i z eo fd o m p e r i d o n e
dispersion in distilled water (1mg domperidone dispersion
suspended in 10mL distilled water) was determined by
dynamic light scattering (DLS) using a Zetasizer Nano-
Instrument (MalvernInstruments, NanoZS,ZEN3600,UK).
2.5. Scanning Electron Microscopy (SEM). SEM analysis was
carried out using a Jeol JSM-5600LV scanning electron
microscope(Japan).Priortoexamination, sampleswere gold
sputter-coated to render them electrically conductive.
2.6. Diﬀerential Scanning Calorimetry (DSC). The DSC
studies were conducted using a Thermal Analysis DSC-
Q100 diﬀerential scanning calorimeter (USA). About 5mg
of samples including raw domperidone, raw PVP, physical
mixture, and domperidone dispersion were encapsulated
in ﬂat-bottomed aluminum pans. The thermograms were
recorded at a heating rate of 10◦C·min−1 from 30 to 280◦C
using nitrogen as the purging gas.
2.7. Powder X-Ray Diﬀraction (PXRD). The powder X-ray
diﬀraction patternswere obtained with a Rigaku Dmax/2400
apparatus (Japan) using Cu-Kα radiation (λ = 1.541nm),
a voltage of 40kV and a 100mA current. Samples were
scanned from 5–30◦ 2θ for qualitative studies and the
scanning rate was 4◦ ·min−1.Journal of Drug Delivery 3
2.8. Solubility Determination. Excess amounts of raw dom-
peridone or domperidone dispersion were added into
50mL polypropylene conical tubes with suitable volume
of buﬀer solution (pH 1.0, 5.0, and 7.0) or distilled
water, respectively. Then, the capped tubes were agitated
at 37◦C in a thermostatically controlled water bath for 48
hours. After equilibrium had been attained, the solutions
were immediately and rapidly ﬁltered through a 0.22μm
Millipore ﬁlter (supplied by Jingteng Science China Corp.)
and the ﬁltrate was diluted with buﬀer solutions or dis-
tilled water. The amount of domperidone in each diluted
sample was analyzed by the HPLC system (Waters Co.
Inc., Westerville, OH, USA), which was equipped with a
1525-pump, 2487-ultraviolet detector, and a Phenomenex
ODS3 (250 × 4.60mm, 5μm) chromatographic column.
The mobile phase, composed of methanol-0.06 M ammo-
nium acetate (70:30), was delivered at 1.0mL/min. The
injection volume was 20μL. The drug was detected at
287nm and the retention time of the drug was ∼10min.
The drug concentration in the ﬁltrate represented its
saturation solubility. The experiment was conducted in
triplicate.
2.9. Preparation of Domperidone Hydrogel. Carbopol 974 P
was dispersed in distilled water. After equilibrated for 24h,
the Carbopol 974 P suspension was neutralised by addition
of triethanolamine (adjusted to pH 7.0–7.5) to obtain the
hydrogel (0.25% w/w). The domperidone dispersion was
directly incorporated into the hydrogel with stirring to
obtain the domperidone hydrogel. The content of domperi-
done in hydrogel was 1mg per mL hydrogel.
2.10. Pharmacokinetic Studies of Domperidone Hydrogel in
Beagle Dogs. Three adult male beagle dogs weighting 9–
11kg, after denied food overnight for at least 12 hours
but had access to water ad libitum, were orally received
marketed domperidone tablet or domperidone hydrogel at
8:00 a.m. with 30mL of distilled water in a crossover manner
with one week washout period, respectively. The dose of
domperidone administered to each dog was 10mg/body. All
the experiments were carried out at the same time of the
day to exclude the inﬂuence of circadian rhythms. After oral
administration of domperidone formulations, blood sample
(about 0.8mL) was collected with glass vials containing
lyophilized sodium heparin from the jugular vein at 0,
0.17, 0.33, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, and 24
hours intervals. After centrifugation at 3000g for 5min,
the plasma samples were obtained and stored at −20◦C
until analysis. The measurement method of domperidone
in plasma was modiﬁed according to the previous report
[26]. Brieﬂy, an aliquot of 400μL plasma samples, 100μL
propranolol solution (25μg/mL, as an internal standard,
the purity was 99.22%), 100μL NaOH (0.1M), 0.5mL
acetonitrile, and 4mL absolute ether were mixed by a vortex
mixer for 1min. The mixture was centrifuged at 5000g
for 10min. Then, a volume of 4.0mL of supernatant was
collected, and dried under a low ﬂow of nitrogen gas at
50◦C in a water bath. The residue was reconstituted using
t h em o b i l ep h a s e( 1 0 0μL), then, an aliquot of this solution
(50μL) was injected onto and assayed by Agilent 1100 HPLC
system consisting of a G1321A spectroﬂuorometric detector
(Agilent Co. Inc., USA). Mobile phase was consisted of
methanol-0.02 M KH2PO4 (48:52, v/v), and delivered at
a ﬂow rate of 1mL/min. Chromatographic separation was
performed on a Phenomenex ODS3 column (250 × 4.6mm,
5 μm, Torrance, CA, USA), and maintained at 30◦Cb ya
column oven. The detector was set at 282nm for excitation
and 328nm for emission wavelength. The peak area of
domperidone(Ad)and propranolol(Ap)were recorded,and
the concentration of domperidome was calculated according
to the ratio of Ad/Ap. The limit of quantiﬁcation (LOQ)
of the assay was 1ng/mL, and linearity was obtained for
domperidone concentrations ranging from 5 to 100ng/mL
(R2 = 0.9978). The coeﬃcients of variation of the interday
and intraday precision of the quality control samples ranged
from 6.4% to 11.4% and accuracy ranged from 101 to
117%.
The pharmacokinetic parameters were calculated from
the plasma levels by noncompartmental pharmacokinetic
analysis using the software package WinNonLin v 5.2
(Pharsight Corporation, Mountain View, CA). The peak
plasma concentration (Cmax)a n dt i m et or e a c hp e a k
plasma concentration (Tmax) was obtained from the visual
inspection of the plasma concentration-time curves. The
area under the plasma concentration curve (AUC0−t)w a s
determined using the trapezoidal rule up to 24 hours after
drug administration.
2.11. The Propulsion Eﬃcacy of Domperidone Hydrogel in
Mice. Kunming mice—after 12 hours of fasting—were
divided into a Motilium tablet group and a domperidone
hydrogel group (n = 8). Mice in this two domperi-
done preparation groups received Motilium tablet (the
Motilium tablet was grinded and suspended in distilled
water) or domperidone hydrogel by intragastric adminis-
tration. The dose of domperidone administered to each
animal was 5mg/kg. After 0.5, 1.0, 1.50, 2.0, 2.5, 3.0,
4.0, and 6.0h administrations, mice received 0.1mL ink
[27]. After 10min, the mice were killed by cervical ver-
tebral dislocation with their stomachs cut open to collect
their intestines. The propulsion eﬃcacy of domperidone
in preparations was presented by ink propulsion rate. The
ink propulsion rate was calculated by using the formula:
ink propulsion rate % = migration distance of ink/the
distance from pylorus-duodenum junction to ileocecum ×
100%. The mice (n = 8) in control group intragastrically
received 0.5mL physiological saline. The ink propulsion
rate was determined according to the procedures outlined
above.
2.12. Statistics. Data was presented as the mean ± standard
deviation (SD). One-way analysis of variance (ANOVA)
was used to determine signiﬁcance among groups, after
which post hoc tests with the Bonferroni correction were
used for comparisons between individual groups. Statistical
signiﬁcance was established at P<. 05.4 Journal of Drug Delivery
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Figure 1: The particle size and distribution of domperidone
dispersion. The particle size of domperidone dispersion in distilled
water (1mg domperidone dispersion suspended in 10mL distilled
water) was determined by dynamic light scattering (DLS).
x10000 1μm
Figure 2: Scanning electron micrographs (SEM) photograph of
domperidone dispersion.
3.Results
3.1. Particle Size Analysis. T h ep a r t i c l es i z eo fd o m p e r i d o n e
dispersion in distilled water was found to be 454.0nm, as
shown in Figure 1. The polydispersity index was 0.115.
3.2. Scanning Electron Microscopy (SEM). The result of SEM
imaging of domperidone dispersion, which is shown in
Figure 2, indicated that the particles had nanometer-size
spherical shapes with a rounded surface appearance and also
that no drug crystal was visible.
3.3.Diﬀerential Scanning Calorimetry (DSC). The DSCther-
mograms of raw domperidone, raw PVP, physical mixture,
and domperidone dispersion are shown in Figure 3.T h e
c u r v eo fr a wd o m p e r i d o n es h o w e da ne n d o t h e r m i cp e a ka t
251.9◦C. In case of the physical mixture, the endothermic
peak of domperidone was broadened, shrunk, and shifted to
125◦C.The completedisappearance ofthedrugendothermic
peak was observed in the domperidone dispersion. This
phenomenon can therefore assume that the domperidone in
the dispersion was in an amorphous form.
3.4. Powder X-Ray Diﬀraction (PXRD). The PXRD patterns
for raw domperidone, raw PVP, domperidone dispersion,
Table 1:Solubilityofdomperidonein buﬀer solutionsand distilled
water (mean ± SD, n = 3). The drug concentration (μg/mL)
represents its solubility.
pH Raw domperidone Domperidone dispersion
1.0 566.8 ± 50.9 36211.8 ± 1.3
5.0 243.3 ± 4.2 3198.4 ± 21.7
7.0 2.9 ± 0.33 10.6 ± 0.27
Distilled water 4.5 ± 0.3 205.5 ± 3.7
and the corresponding physical mixture are shown in
Figure 4.I nt h eX - r a yd i ﬀraction spectrum, domperidone
exhibited several strong characteristic crystalline peaks at
2θ = 9.28◦, 13.94◦, 15.58◦, 19.80◦, and 24.80◦ in raw
domperidone, suggesting that the drug was present as a
crystalline material. Some domperidone crystal peaks were
still detected in the physical mixtures. In contrast, there
were no sharp peaks attributable to the crystalline form
in domperidone dispersion, suggesting that domperidone
in this dispersion was in an amorphous state. This result
conﬁrmed the result obtained from DSC.
3.5. Solubility. The solubility of domperidone in raw dom-
peridone and domperidone dispersion is presented in
Table 1. In distilled water, the solubility of domperidone
in the dispersion was 205.5 ± 3.7μg/mL, 45.7-fold higher
than that of raw domperidone (4.5 ± 0.3μg/mL). In pH
1, 5 and 7 buﬀer solution, the solubility of domperidone
in dispersion were 36211.8 ± 1.3, 3198.4 ± 21.7 and 10.6
± 0.27μg/mL, 63.9-, 13.1- and 3.7-fold higher than that of
raw domperidone (566.8 ± 50.9, 243.3 ± 4.2, and 2.9 ±
0.33μg/mL), respectively.
3.6. Pharmacokinetic Studies of Domperidone Hydrogel in
Beagle Dogs. The in vivo pharmacokinetic results obtained
for the formulation based on domperidone hydrogel were
compared with Motiliumtablet. Figure 5 showed the average
plasma concentration versus time curves of domperidone
after oral administration of preparations to beagle dogs at
a dose of 10mg/body. The concentrations of domperidone
in hydrogel treatment group, especially in last time points,
were remarkable higher than that in tablet treatment group
(P<. 05).
As shown in Table 2, administration of Motilium tablet
resulted in AUC0−24 values of 382.11 ± 52.71h·ng/mL.
When the same dose of domperidone was formulated
in hydrogel, the systemic exposure to domperidone was
raised signiﬁcantly as reﬂected in an AUC0–24) of 829.64 ±
105.09h·ng/mL higher than that from tablet (P<. 01).
In terms of Cmax, the values from hydrogel group (70.05 ±
12.27ng/mL) were higher than those from tablet group
(56.95 ± 6.63ng/mL), however, there was no signiﬁcant
diﬀerence between these two groups. Based on a comparison
of the Tmax values, the Cmax reached time in hydrogel group
(1.17 ± 0.29h) was signiﬁcantly longeras compared to tablet
group (0.44 ± 0.10h) (P<. 01). In addition, the diﬀerencesJournal of Drug Delivery 5
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Figure 3: Diﬀerential scanning calorimetry (DSC) of raw domperidone (1), raw PVP K30 (2), physical mixture of domperidone and PVP
K30 (3), and domperidone dispersion (4).
Table 2: Selected pharmacokinetic parameters of domperidone
after a single administration of Motilium tablet or domperidone
hydrogel to beagle dogs at a dose of 10mg/body (n = 3).
Parameter Units Motilium tablet Domperidone hydrogel
Tmax h 0.44 ± 0.10 1.17 ± 0.29∗∗
Cmax ng/mL 56.95 ± 6.63 70.05 ± 12.27
AUC0−24 h·ng/mL 382.11 ± 52.71 829.64 ± 105.09∗∗
Vz l/kg 35.16 ± 2.06 17.49 ± 2.17∗
Cl l/h/kg 2.04 ± 0.26 0.93 ± 0.08∗∗
MRT h 10.04 ± 1.05 10.85 ± 0.49
∗P<. 05 or ∗∗P<. 01 versus tablet group.
in the values of Vz and Cl between hydrogel group and tablet
group (P<. 05 or P<. 01) could also be noted.
3.7. The Propulsion Eﬃcacy of Domperidone Hydrogel in
Mice. Figure 6 shows the ink propulsion rates of small
intestine in mice after they were administered intragastric
Motilium tablet, domperidone hydrogel, or physiological
Table 3: The ink propulsion rate of the small intestine at peak
time or 6h time point after an intragastric given Motilium tablet
or domperidone hydrogel to mice at a dose of 5mg/kg and the
average ink propulsion rate of the small intestine after intragastric
given physiological saline to mice. Each point represents mean ±
S.D. (n = 8).
Ink propulsion rate
(%) Average Peak time 6ht i m e
point
Physiologicalsaline
group 41.9 ± 9.9 / /
Motilium tablet
group / 57.1 ± 11.5∗ 38.3 ± 13.2
Domperidone
hydrogel group / 71.5 ± 13.3∗∗
￿ 58.0 ± 9.1∗
￿
∗P<. 05, ∗∗P<. 01 versus physiological saline group.
￿P<. 05 versus tablet group.
saline. The ink propulsionrates in domperidone preparation
groups at peak time were signiﬁcantly higher than that in
tablet or physiological saline group (P<. 05 or P<. 01),6 Journal of Drug Delivery
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Figure 4: Powder X-ray diﬀractogram (PXRD) of raw domperidone (1); raw PVP K30 (2); physical mixture of domperidone and PVP K30
(3); domperidone dispersion (4).Journal of Drug Delivery 7
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Figure 5: Concentration-time proﬁles of domperidone in plasma
after a single oral administration of domperidone hydrogel or
Motilium tablet to beagle dogs at a dose of 10mg/body. Each point
represents mean ± S.D. (n = 3). The asterisks indicate a statistically
signiﬁcant diﬀerence between domperidone hydrogel group and
Motilium tablet group (P<. 05).
as shown in Table 3.T h ed i ﬀerence in ink propulsion rates at
peaktimepointbetweenthehydrogelgroupandtabletgroup
were signiﬁcant (P<. 05). The values of ink propulsion rates
at 6h time point in hydrogel group compared with the tablet
or physiological saline group were signiﬁcant higher (P<
.05), whereas there was no signiﬁcant diﬀerence between the
physiological saline group and tablet group (Table 3).
The peak time of ink propulsion rates in domperidone
hydrogelgroupandtabletgroupwas1.5and1h,respectively.
In fact, the values of ink propulsion rates in domperidone
hydrogel group at 0.5h time points, (60.1 ± 14.0)%, was
similar with those in tablets group in 1h time point (at peak
time point, (57.1 ± 11.5)%), indicating that the onset time
of propulsion eﬃcacy in hydrogel group was faster than that
in tablet group. The propulsion eﬃcacy in the domperidone
hydrogel group was sustained at least 6h; however, it was
sustained only 3h in tablet group, indicating the prolonged
propulsion eﬃcacy in hydrogel group compared to that in
tablet group.
4.Discussion
Inthepresentstudy,weprepareddomperidonedispersionby
evaporationmethodusingPVP asapolymericcrystallization
inhibitor. The amorphous domperidone in dispersion was
c o n ﬁ r m e db yD S Ca n dX - r a yt e s t s .T h ep a r t i c l es i z eo fd o m -
peridone dispersion in distilled water and the morphology
of domperidone dispersion indicated that the domperidone
dispersion was in the nanometer size range. The solubility
of domperidone in the dispersion in distilled water was
found to be 45.7-fold higher than that of raw domperidone.
Similarresults were also found inpH 1 and 5 buﬀersolution,
63.9- and 13.1-fold higher than that of raw domperidone.
The higher solubility of domperidone in the dispersion
would provide a guarantee of enhancing the absorption of
domperidone in GIT.
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Figure 6: Proﬁles of the ink propulsion rates of the small intes-
tine after intragastric administered Motilium tablet, domperidone
hydrogel, or physiological saline to mice. Each point represents
mean ± S.D. (n = 8). The dose of domperidone was 5 mg/kg.
The asterisks indicate a statistically signiﬁcant diﬀerence between
domperidone hydrogel group and physiological saline group (∗P<
.05; ∗∗P<. 01).
The solubility of domperidone in dispersion in pH 7.0
buﬀersolutionwas 10.6μg/mL. Accordingtothe calculation,
about 99.9% domperidone dispersion existed as solid nano-
sized particles in this solution. Therefore, we suggest that
almost all of the domperidone dispersion in the Carbopol
hydrogels would exist as solid nanosized particles.
Carbopol is a very useful polymer for hydrogel delivery
system [28, 29]. The incorporation of nanoparticles with
hydrogel would increase its adhesive properties to GIT.
This is a beneﬁt for enhancing drug oral bioavailability.
I na d d i t i o n ,C a r b o p o lh y d r o g e lh a st h ec h a r a c t e r i s t i co fa
higher viscosity, which could limit the sedimentation of
the contained particles. Excellent long-term stability of the
hydrogel/drug nanoparticles system has been observed by
M¨ ullerandJacobs[25].Evenso,thestabilityofdomperidone
dispersion existed as nanosize particles in the Carbopol
hydrogel should be further investigate in future.
The physical properties of the Carbopol hydrogels are
extremely sensitive to the presence and concentration of
additives [30]. It has been reported that for Carbopol
hydrogels with 0.05 and 0.1% of PVP, the behavior is similar
to that of single Carbopol formulation, their pseudoplastic
non-Newtonian character being maintained [21]. Therefore,
in the present research, the addition of PVP does not sub-
stantially modify the rheological behavior of the Carbopol
hydrogels.
Considering the advantages of amorphous dispersion
and adhesive properties of hydrogel to the GIT wall, we
incorporateddomperidonedispersion with Carbopolhydro-
gel to prepare a novel domperidone hydrogel. The in vivo
pharmacokinetic evaluation of domperidone hydrogel in
dogs was investigated. The positive pharmacokinetic results8 Journal of Drug Delivery
showed that the AUC in domperidone hydrogel was 2.2-
fold higher than that in Motilium tablet. The concentrations
of domperidone in hydrogel treatment group, especially
in last time points, were remarkable higher than that in
tablet treatment group (P<. 01). The results of in vivo
pharmacodynamic evaluation in mice indicated that the
higher and prolonged propulsion eﬃcacy was observed in
the domperidone hydrogel group compared to that in tablet
group. We suggested that the particle size of domperidone
reduction to a nanometer range and the conversion of
crystalline drug to amorphous state in dispersion resulted
in an increase of dissolution velocity and degree of the
drug in the GIT, especially in gastric ﬂuid. Therefore, the
rapid and complete absorption from the gastrointestinal
tract would lead to improving the bioavailability and the
propulsion eﬃcacy of domperidone in hydrogel group.
Another reason for the in vivo results was the role of
Carbopol hydrogel which prolonged the residence and
the contact time of domperidone in GIT. The sustained
release behavior in domperidone hydrogel group was con-
ﬁrmed by our pharmacokinetic and pharmacodynamic
results.
5.Conclusion
The characterization of domperidone dispersion demon-
strated that the prepared domperidone dispersion were
amorphous and in the nanometer size range. Solubility of
domperidone in the dispersion showed a marked increase.
The domperidone hydrogel was prepared by directly incor-
porating the domperidone dispersion in Carbopol hydrogel.
As a result of the mucoadhesive properties and improved
solubility, a statistically signiﬁcant improvement in bioavail-
ability and prolonged propulsion eﬃcacy of domperidone in
hydrogel group were observed compared to that in Motilium
tablet group in beagle dogs and mice. In addition, these
results indicate that dispersion incorporating with hydrogel
c a nb ea ne ﬀective tool to improve the bioavailability of poor
water soluble drugs.
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